NO954643L - Antistoff-fragment samt anvendelse og framgangsmåte for framstilling av samme - Google Patents

Antistoff-fragment samt anvendelse og framgangsmåte for framstilling av samme

Info

Publication number
NO954643L
NO954643L NO954643A NO954643A NO954643L NO 954643 L NO954643 L NO 954643L NO 954643 A NO954643 A NO 954643A NO 954643 A NO954643 A NO 954643A NO 954643 L NO954643 L NO 954643L
Authority
NO
Norway
Prior art keywords
same
preparing
well
antibody fragment
treatment
Prior art date
Application number
NO954643A
Other languages
English (en)
Norwegian (no)
Other versions
NO954643D0 (no
Inventor
John Landon
Original Assignee
Therapeutic Antibodies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939311507A external-priority patent/GB9311507D0/en
Priority claimed from GB9402593A external-priority patent/GB9402593D0/en
Application filed by Therapeutic Antibodies Inc filed Critical Therapeutic Antibodies Inc
Publication of NO954643D0 publication Critical patent/NO954643D0/no
Publication of NO954643L publication Critical patent/NO954643L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pens And Brushes (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
NO954643A 1993-06-03 1995-11-17 Antistoff-fragment samt anvendelse og framgangsmåte for framstilling av samme NO954643L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939311507A GB9311507D0 (en) 1993-06-03 1993-06-03 Antibody fragments
GB9402593A GB9402593D0 (en) 1994-02-10 1994-02-10 Antibody fragments
PCT/GB1994/001209 WO1994029347A1 (fr) 1993-06-03 1994-06-03 Utilisation de fragments d'anticorps en therapie

Publications (2)

Publication Number Publication Date
NO954643D0 NO954643D0 (no) 1995-11-17
NO954643L true NO954643L (no) 1995-11-17

Family

ID=26303001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954643A NO954643L (no) 1993-06-03 1995-11-17 Antistoff-fragment samt anvendelse og framgangsmåte for framstilling av samme

Country Status (16)

Country Link
US (2) US5733742A (fr)
EP (3) EP0703925B1 (fr)
JP (1) JP2953782B2 (fr)
AT (2) ATE183513T1 (fr)
AU (2) AU678483B2 (fr)
CA (1) CA2163032C (fr)
DE (2) DE69420137T2 (fr)
DK (2) DK0701571T3 (fr)
ES (2) ES2108460T3 (fr)
FI (1) FI955798L (fr)
GB (1) GB2294267B (fr)
GR (2) GR3025133T3 (fr)
NO (1) NO954643L (fr)
NZ (1) NZ266838A (fr)
RU (1) RU2139092C1 (fr)
WO (2) WO1994029347A1 (fr)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
GB9517538D0 (en) * 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
MX336813B (es) 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
CA2249206A1 (fr) 1996-04-01 1997-10-09 Genentech, Inc. Polypeptides de l'apoptose apo-2l1 et apo-3
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6291643B1 (en) 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
IL133122A0 (en) 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
ATE443723T1 (de) 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EP1326892A2 (fr) 2000-10-12 2003-07-16 University of Rochester Compositions inhibant la proliferation de cellules cancereuses
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
WO2003065997A2 (fr) 2002-02-06 2003-08-14 Vicor Technologies, Inc. Molecules anti-infarcissement
JP2005521429A (ja) 2002-03-25 2005-07-21 ユーエービー リサーチ ファウンデーション Ｆｃレセプターホモログ、試薬およびこれらの使用
ES2365210T3 (es) 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
EP1575992A4 (fr) 2002-08-05 2007-02-21 Univ Rochester Proteines chimeres a domaine de transduction proteique/domaine desaminase, composes associes et utilisations correspondantes
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1576351A4 (fr) 2002-11-26 2010-06-23 Univ Utah Res Found Materiaux microporeux, procedes, et articles permettant de localiser et de quantifier des analytes
US7597936B2 (en) 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
US7335759B2 (en) * 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7141015B2 (en) * 2003-05-09 2006-11-28 Bernard Joseph Ruane Expandable and pivotally adjustable surgical retractor
EP1651266B1 (fr) * 2003-07-25 2010-03-03 Laboratorios Silanes, S.A. de C.V. Administration de fragments d'anticorps f(ab')2 anti-tnf-alpha
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
EP1711517A4 (fr) 2004-01-21 2008-02-13 Univ Utah Res Found CANAL SODIQUE NAv1.7 MUTANT ET PROCEDES ASSOCIES
PT1730191E (pt) 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
CA2575402A1 (fr) 2004-08-05 2006-02-09 Genentech, Inc. Antagonistes anti-cmet humanises
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
AU2005332058B2 (en) 2005-05-19 2011-12-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
EP1806365A1 (fr) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2644952A1 (fr) 2006-03-01 2007-09-13 The University Of Utah Research Foundation Procedes et compositions relatifs a la synthese de peptides cycliques
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
CA2656347A1 (fr) 2006-07-03 2008-01-10 Charles David Adair Composition servant a moduler l'expression de molecules d'adherence cellulaire
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
US10094836B2 (en) 2007-01-08 2018-10-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SLCO1B3 genotype
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US8097588B2 (en) 2007-02-08 2012-01-17 Sanford-Burnham Medical Research Institute Trophinin-binding peptides and uses thereof
EP2478766A3 (fr) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Ciblage de protéinases hôtes en tant que stratégie thérapeutique contre des pathogènes viraux et bactériens
CN101688194B (zh) 2007-05-23 2013-09-11 Uab研究基金会 去毒的肺炎球菌神经氨酸酶及其用途
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2010070380A2 (fr) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Compositions doc1 et méthodes de traitement du cancer
CA2711984A1 (fr) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Composition de proteine pulverisee et procedes de fabrication de celle-ci
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
EP4071169A2 (fr) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Épitope d'hémagglutinine de la grippe conservé et anticorps associés
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
WO2011020107A2 (fr) 2009-08-14 2011-02-17 Georgetown University Compositions et méthodes de dépistage et de traitement du cancer du sein
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
WO2011080050A2 (fr) 2009-12-11 2011-07-07 Novartis Ag Molécules de liaison
CA2784145A1 (fr) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methodes et compositions associees aux composes de liaison aux caillots
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
PE20170687A1 (es) 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US20110293629A1 (en) 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
CN103201290B (zh) 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
WO2012023938A1 (fr) 2010-08-19 2012-02-23 West Pharmaceutical Services, Inc. Gaine d'aiguille rigide
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes
PL221015B1 (pl) * 2011-04-11 2016-02-29 Akademia Medyczna Im Piastów Śląskich Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012161856A1 (fr) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blocage des interactions tl1a-dr3 pour améliorer la pathologie des maladies médiées par les cellules t et anticorps afférents
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
US9846159B2 (en) 2011-09-30 2017-12-19 Sarcotein Diagnostics, Llc BIN1 expression as a marker of cancer
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
US9177997B2 (en) 2011-12-13 2015-11-03 Sony Corporation Memory device
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
IN2015MN00001A (fr) 2012-06-08 2015-10-16 Univ Kinki
EP2870238A4 (fr) 2012-07-05 2016-03-09 Ohio State Innovation Foundation Compositions et procédés associés à des vaccins viraux
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
WO2014085821A2 (fr) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticorps entièrement humains et fragments reconnaissant la protéine c-met humaine
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
WO2014201118A2 (fr) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions et méthodes de traitement ciblé de l'endométriose
TWI636065B (zh) 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015069459A1 (fr) 2013-11-05 2015-05-14 Novartis Ag Composés organiques
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US10247729B2 (en) 2014-05-05 2019-04-02 Microbplex, Inc. Media elaborated with newly synthesized antibodies (MENSA) and uses thereof
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49156A (fr) 2014-12-23 2020-03-25 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
WO2016141088A1 (fr) 2015-03-02 2016-09-09 Sarcotein Diagnostics, Llc Expression de bin1 13+/17+ à utiliser en tant que marqueur de troubles cardiaques
LT3388075T (lt) 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20230563A (es) 2015-07-06 2024-01-22 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
WO2017160587A1 (fr) 2016-03-16 2017-09-21 Abeome Corporation Anticorps monoclonaux neutralisants dirigés contre l'il-25 et leurs utilisations
CN109071605A (zh) 2016-04-06 2018-12-21 伊玛提克斯生物技术有限公司 用于aml和其他癌症免疫治疗的新型肽和肽组合物
RS61510B1 (sr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anti pd-1 i anti-lag3 antitela za lečenje kancera
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DK3523416T3 (da) 2016-10-05 2025-03-03 Univ Central Florida Res Found Inc Fremgangsmåder og sammensætninger relateret til nk-celle- og anti-pdl1-kræftbehandlinger
EP3360898A1 (fr) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer
WO2018118887A1 (fr) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
WO2018138257A1 (fr) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
ES2963046T3 (es) 2017-03-20 2024-03-25 Vaccinex Inc Tratamiento del cáncer con un anticuerpo contra la semaforina-4d combinado con un agente modulador epigenético
ES2963635T3 (es) 2017-03-28 2024-04-01 Ohio State Innovation Foundation Vacunas de péptido PD1 humano y usos de las mismas
EP3385699A1 (fr) 2017-04-07 2018-10-10 Universitat Rovira i Virgili Dispositif optofluidique et procédé de détection de cellules tumorales circulantes
BR112019020959A2 (pt) 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
WO2018189148A1 (fr) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
MX2019015879A (es) 2017-07-07 2020-02-07 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinacones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres.
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
AU2018298971B2 (en) 2017-07-14 2025-01-23 Cancer Research Technology Limited Analysis of HLA alleles in tumours and the uses thereof
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2019070108A1 (fr) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Processus à haut rendement pour la production d'antivenins à partir de fragments d'anticorps f(ab') 2
US12053523B2 (en) 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
EP3569618A1 (fr) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonisation d'anticorps cd73
WO2019236590A1 (fr) 2018-06-04 2019-12-12 University Of Maryland, Baltimore Méthodes de prévention d'une lésion rénale aiguë
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
CA3104664A1 (fr) 2018-06-29 2020-01-02 North Carolina State University Gel immunotherapeutique biosensible pulverise in situ pour un traitement post-chirurgical
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
EP4588483A3 (fr) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Synnotch adaptateur covalent et récepteurs d'antigènes chimériques (cars) pour ciblage d'antigène programmable
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020115223A1 (fr) 2018-12-05 2020-06-11 Katholieke Universiteit Leuven S100a4 utilisable en tant que marqueur de traitement par la spironolactone, la pioglitazone et la metformine
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
WO2020139782A1 (fr) 2018-12-27 2020-07-02 University Of Utah Research Foundation Compositions et procédés utiles dans la détection et le traitement de la sclérose en plaques et d'autres maladies démyélinisantes
WO2020206233A1 (fr) 2019-04-04 2020-10-08 Vanderbilt University Anticorps thérapeutiques pour le traitement du cancer du poumon
WO2020225549A1 (fr) 2019-05-06 2020-11-12 The Francis Crick Institute Limited Procédé de prévention de l'inflammation
CA3135592A1 (fr) 2019-05-20 2020-11-26 Xiaochao Ma Agents therapeutiques pour la protoporphyrie erythropoietique (ppe) et la protoporphyrie liee au chromosome x (plx)
IL288779B2 (en) 2019-06-21 2025-11-01 Vaccinex Inc Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
US12594278B2 (en) 2019-07-16 2026-04-07 Children's National Medical Center Method for treatment of muscular dystrophy
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
MX2022003195A (es) 2019-09-18 2022-04-11 Molecular Templates Inc Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.
WO2021055816A1 (fr) 2019-09-18 2021-03-25 Molecular Templates, Inc. Molécules de liaison pd-l1 comprenant des échafaudages de la sous-unité a de la shiga-toxine
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
WO2021067550A1 (fr) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
EP4093884A4 (fr) 2020-01-24 2024-05-15 Vanderbilt University Méthodes d'identification d'anticorps de blocage de ligand et de détermination de la puissance d'anticorps
JP7785693B2 (ja) 2020-05-08 2025-12-15 ノボキュア ゲーエムベーハー 多能性幹細胞に交流電場を印加する組成物及び方法
WO2021236658A1 (fr) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Molécules de liaison pour le traitement du cancer
WO2021237055A1 (fr) 2020-05-21 2021-11-25 Ohio State Innovation Foundation Dérivés lipidiques fonctionnels et leurs utilisations
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
EP4232474A1 (fr) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Molécules de liaison anti-vegf et anti-trkb bispécifiques pour le traitement de maladies oculaires
EP4262858A1 (fr) 2020-12-16 2023-10-25 Molecular Templates, Inc. Méthodes cliniques pour l'utilisation d'une molécule de liaison pd-l1 comprenant un effecteur de toxine de shiga
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
US20250011405A1 (en) 2021-11-19 2025-01-09 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN114132883B (zh) * 2021-11-29 2023-12-22 义乌市奥飞创意设计有限公司 一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备
IL317689A (en) 2022-07-15 2025-02-01 Boehringer Ingelheim Int Binding molecules for cancer treatment
EP4615874A1 (fr) 2022-11-10 2025-09-17 Immuvia Inc Anticorps bispécifiques cytotoxiques se liant à dr5 et muc16 et leurs utilisations
WO2025040598A2 (fr) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides affichés par cmh destinés à être utilisés en immunothérapie contre différents types de cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS58501544A (ja) 1981-09-08 1983-09-16 ザ　ロツクフエラ−　ユニヴア−シテイ エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
CA1260828A (fr) 1983-07-04 1989-09-26 Masakazu Iwai Agent prophylactique et therapeutique contre les ulceres gastrointestinaux
DE3342870A1 (de) 1983-11-26 1985-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4684623A (en) 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
EP0613006A1 (fr) 1985-08-16 1994-08-31 The Rockefeller University Anticorps contre cachectin et essais immunologiques
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
AU616161B2 (en) 1986-10-09 1991-10-24 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
DE3823804A1 (de) * 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
WO1990001950A1 (fr) 1988-08-19 1990-03-08 Celltech Limited Produits pharmaceutiques pour therapie anti-neoplastique
ATE147634T1 (de) 1988-12-19 1997-02-15 American Cyanamid Co Produkte zur behandlung des endotoxin -schocks bei einem säugetier
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
WO1991007986A1 (fr) * 1989-12-04 1991-06-13 Schering Corporation Methode de traitement de choc septique
US5110913A (en) * 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
GB9023783D0 (en) * 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
EP1857553A1 (fr) * 1991-03-18 2007-11-21 New York University Anticorps monoclonaux et chimériques spécifiques pour le facteur onconécrosant humain
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
WO1993011793A1 (fr) * 1991-12-17 1993-06-24 Schering Corporation Utilisation de la combinaison du facteur de necrose anti-tumeur et de l'interleukine-6 dans le traitement du choc septique
CA2146647C (fr) 1992-10-08 2009-05-05 Marc Feldmann Traitement d'affections auto-immunes et inflammatoires
WO1994010980A1 (fr) 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions comprenant des anticorps de neutralisation microencapsules
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten

Also Published As

Publication number Publication date
DK0703925T3 (da) 1999-12-06
NZ266838A (en) 1997-02-24
ATE183513T1 (de) 1999-09-15
EP0916678A3 (fr) 1999-05-26
FI955798A7 (fi) 1996-02-01
JP2953782B2 (ja) 1999-09-27
DE69405102D1 (en) 1997-09-25
GB2294267A (en) 1996-04-24
JPH08511015A (ja) 1996-11-19
EP0701571B1 (fr) 1997-08-20
ES2138662T3 (es) 2000-01-16
CA2163032A1 (fr) 1994-12-22
EP0703925B1 (fr) 1999-08-18
US5733742A (en) 1998-03-31
GB9524064D0 (en) 1996-02-21
DE69405102T2 (de) 1998-01-15
NO954643D0 (no) 1995-11-17
CA2163032C (fr) 2001-02-06
WO1994029348A2 (fr) 1994-12-22
WO1994029347A1 (fr) 1994-12-22
FI955798L (fi) 1996-02-01
DK0701571T3 (da) 1997-09-15
DE69420137D1 (de) 1999-09-23
GR3025133T3 (en) 1998-02-27
GB2294267B (en) 1996-11-20
ATE157100T1 (de) 1997-09-15
EP0701571A1 (fr) 1996-03-20
US6193969B1 (en) 2001-02-27
DE69420137T2 (de) 1999-12-23
EP0703925A1 (fr) 1996-04-03
AU6852594A (en) 1995-01-03
GR3031415T3 (en) 2000-01-31
FI955798A0 (fi) 1995-12-01
AU678483B2 (en) 1997-05-29
RU2139092C1 (ru) 1999-10-10
AU6852494A (en) 1995-01-03
EP0916678A2 (fr) 1999-05-19
ES2108460T3 (es) 1997-12-16

Similar Documents

Publication Publication Date Title
NO954643L (no) Antistoff-fragment samt anvendelse og framgangsmåte for framstilling av samme
NO942850D0 (fr)
FI954347L (fi) Monoklonaaliset vasta-ainekoostumukset ja monoklonaalisia vasta-aineita tuottavat hybridomat
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
AU1518795A (en) Immunoassays for prostate specific antigen
EP1097945A3 (fr) Anticorps monoclonaux et chimères dirigés spécifiquement contre le facteur humain de nécrose de tumeurs
CA2004478A1 (fr) Anticorps monoclonaux contre le lentivirus t-lymphotrope felin
NO302176B1 (no) Fremgangsmåte for fremstilling av et monoklonalt antistoff og et antigen
NO960349D0 (no) Immunanalyse for påvisning av kollagen eller kollagenfragmenter
AU7345487A (en) Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen
AU7473087A (en) Apparatus for immunoassay with antibody or antigen attached to walls
AU525403B2 (en) Purified antigen
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
HUT63205A (en) Process for producing monoclonal antibodies and their fragments
YU46858B (sh) Postupak za dobijanje imunoglobulinskih konjugata
EP0323802A3 (fr) Anticorps monoclonaux contre, et antigène de la surface cellulaire de cancer du poumon
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ATE133075T1 (de) Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
CA2054689A1 (fr) Une methode d'immunoessai pour determiner la specificite de liaison entre un anticorps monoclonal et un antigene
JPS57208458A (en) Labeled antibody for immunochemical measurement
DK329789A (da) Monoklonalt antistof
NO974793D0 (no) Fremgangsmåte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav
WO1987007302A3 (fr) ANTICORPS MONOCLONAUX DES RECEPTEURS IgE DES LYMPHOCYTES HUMAINS, HYBRIDOMES PRODUISANT DE TELS ANTICORPS, ET KITS POUR UTILISER CES ANTICORPS
AU4465489A (en) Monoclonal antibody specifically recognizing n-glycolyl type gm2 hybridoma producing the antibody and method for preparing the hybridoma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application